Showing 91-100 of 10577 results for "".
- Academy for Global Interprofessional Learning and Education (AGILE) - Programshttps://reachmd.com/programs/academy-global-interprofessional-learning-and-education-agile/
- Surgery - CMEhttps://reachmd.com/cme/surgery/
- Surgery - Clinical Practicehttps://reachmd.com/clinical-practice/surgery/
Vous prescrivez uniquement des antihistaminiques pour traiter les patients atteints de Pa-MRC ? Il est temps de revoir votre approche !
https://reachmd.com/programs/cme/vous-prescrivez-uniquement-des-antihistaminiques-pour-traiter-les-patients-atteints-de-pa-mrc-il-est-temps-de-revoir-votre-approche/56888/Examinez un cas clinique réel de Pa-MRC et explorez les options thérapeutiques actuelles, y compris l’utilisation de la difélikéfaline, recommandée par les lignes directrices, chez les patients sous hémodialyse.The Credit Crunch
https://reachmd.com/programs/clinicians-roundtable/the-credit-crunch/1402/In a credit crunch, lenders stop lending and credit becomes tough to obtain. The snowball effect of a credit crunch can eventually impact the entire economy. Are we in a credit crunch? What can investors do to protect themselves?FCS: Enhancing the Diagnosis
https://reachmd.com/programs/cme/fcs-enhancing-the-diagnosis/33220/Listen to experts discussing the latest developments in APOC3 inhibition for the treatment of patients with FCS, SHTG, and mixed hyperlipidemia.FUE vs FUT: Key Considerations for Patient Selection
https://reachmd.com/programs/dermconsult/fue-fut-patient-selection-considerations/49026/Understanding the differences between follicular unit extraction (FUE) and follicular unit transplantation (FUT) is essential for selecting the most appropriate approach for each patient. Dr. Marc Avram shares how harvesting methods, scarring patterns, and other patient-specific consideratioThe Road Ahead: What's on the Horizon for FCS and SHTG Management
https://reachmd.com/programs/cme/the-road-ahead-whats-on-the-horizon-for-fcs-and-shtg-management/33228/Listen to experts discussing the latest developments in APOC3 inhibition for the treatment of patients with FCS, SHTG, and mixed hyperlipidemia.Latest Clinical Trial Outcomes and Breakthroughs for FCS
https://reachmd.com/programs/cme/latest-clinical-trial-outcomes-and-breakthroughs-for-fcs/33223/Listen to experts discussing the latest developments in APOC3 inhibition for the treatment of patients with FCS, SHTG, and mixed hyperlipidemia.APOC3 Inhibition: New Frontiers Managing Patients with FCS & SHTG
https://reachmd.com/programs/cme/apoc3-inhibition-new-frontiers-managing-patients-with-fcs-shtg/20307/Listen to experts discussing the latest developments in APOC3 inhibition for the treatment of patients with FCS, SHTG, and mixed hyperlipidemia.